Figure 4From: A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma Analysis of GV1001 specific T cell responses by ELISA (A) and thymidine incorporation (B) in HCC patients before and after peptide vaccination. Among 11 patients analyzed no definite antigen-specific T cell responses were noticed.Back to article page